TAT-014

N/A

Report date: 2023/05/05 17:36:45

Base Information

Drug NameTAT-014
Drug Alias NameTAT-014BCIA-07
ClassificationBiologics > Protein drugs > Immunoglobulin > Antibody > Monoclonal antibody
Mechanisms of ActionAntibody-dependent cell-mediated cytotoxicity (ADCC) effectsComplement dependent cytotoxicity (CDC) effectsCD20-directed cytolytic effects +[4] 
TargetsB-lymphocyte antigen CD20
Therapy Area/IndicationsLymphoma, Mantle-Cell
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryMainland China
CombinationsNo
Global Highest StatusPreclinical
Highest Status in ChinaPreclinical
Originator CompaniesTot Biopharm International Company Ltd
China Registration ClassN/A

Develop Information

Active CompaniesTot Biopharm International Company Ltd
Inactive CompaniesN/A
Active IndicationsLymphoma, Mantle-Cell
Inactive IndicationsN/A

Other Information

ATC CodeN/A
Related LinksN/A